Autolus Therapeutics plc cotiza a 1.74 USD y tiene una capitalización bursátil de $463M. En los últimos 12 meses ha facturado $117M con un margen de flujo de caja libre del -401.4%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | — | $-0.27 | $-0.34 |
| Estimado | $-0.19 | $-0.19 | $-0.26 | $-0.27 |
| Sorpresa | — | — | -3.8% | -25.9% |
| Métrica | AUTL | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | -27.8% | 57.0% | -84.9% |
| Operating Margin | -358.9% | -38.6% | -320.3% |
| Net Margin | -381.4% | -33.6% | -347.8% |
| FCF Margin | -401.4% | -13.9% | -387.5% |
| ROE | -161.4% | -40.4% | -121.0% |
| ROA | -48.8% | -32.0% | -16.8% |
| Current Ratio | 5.94 | 2.84 | +3.10 |
| Debt / Equity | — | 0.28 | — |